US Raises Concerns Over Possible ASML EUV Machine Transfer to China 
BHP Shares Fall as Jansen Potash Project Costs Surge 
Frank Stronach Found Guilty of Sexual Assault and Indecent Assault in Ontario Court 
Kingboard Holdings Shares Surge After HK$11.77 Billion Block Trade to Expand PCB and AI Supply Chain Business 
Apple Signals Product Price Hikes Amid Rising Memory Chip Costs 
J.P. Morgan Sees Potential Vestas Guidance Upgrade Amid Strong Wind Energy Demand 
SK Hynix Shares Hit Record High After Shipping Next-Generation HBM4E AI Memory Samples 
SpaceX Surpasses Amazon in Market Value as Post-IPO Rally Accelerates 
Microsoft Taps AWS to Support GitHub Amid AI Coding Boom 
Carro Expands Into Australia With Acquisition of Used-Car Platform CarPlace 
Jio IPO Filing Nears as Reliance Targets $4 Billion Market Debut 
Obayashi to Acquire Multiplex in $526M Expansion Deal 
SpaceX Stock Slides After IPO Rally as Valuation Concerns Grow 
SoftBank Shares Drop as OpenAI Losses and Rising Costs Spark Investor Concerns 
Qantas Nears Launch of World’s Longest Non-Stop Flights to London and New York 
Qantas Unveils Wellness-Focused Nonstop Sydney-London Flights to Reduce Jet Lag 
GM and Lockheed Martin Partner to Strengthen U.S. Defense Manufacturing Capacity 
OXFORD, United Kingdom, Jan. 07, 2016 (GLOBE NEWSWIRE) -- Midatech Pharma (AIM:MTPH) (Nasdaq:MTP), the international specialty pharmaceutical company focused on developing and commercialising products in oncology and other therapeutic areas, today announced that it will present at the Biotech Showcase™ 2016 to be held January 11-13 at the Parc 55 Hotel in San Francisco.
Dr. Jim Phillips, Chief Executive Officer of Midatech Pharma, will present a company overview on Monday, January 11, 2016 at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time). A live audio webcast of the presentation will be available to be accessed at http://edge.media-server.com/m/p/y9pmodcz or from Midatech’s website at the Media, Events section www.midatechpharma.com. An archived version of the webcast will be available for 90 days.
About Midatech Pharma PLC
Midatech is an international specialty pharmaceutical company focused on oncology and other therapeutic areas with a commercial platform and four marketed products in the US. Midatech’s strategy is to develop products in-house in oncology and with partners in other indications, and to accelerate growth organically and through strategic acquisitions. The Company’s R&D activities are supported by two breakthrough drug delivery technologies. The Group, listed on AIM: MTPH and Nasdaq: MTP, employs c.100 staff in four countries. For further company information see: www.midatechpharma.com
For more information, please contact: Midatech Pharma PLC Jim Phillips, CEO Tel: +44 (0)1235 841575 www.midatechpharma.com Panmure Gordon (UK) Limited (Nominated Adviser and Joint Broker) Corporate Finance Freddy Crossley / Adam James / Atholl Tweedie / Duncan Monteith Broking Tom Salvesen Tel: +44 (0)20 7886 2500 RBC Europe Limited (Joint Broker) Darrell Uden / Paul Tomasic / Rupert Walford / Thomas Stockman Tel: +44 (0)207 653 4000 Consilium Strategic Communications (Financial PR) Mary Jane Elliott / Ivar Milligan / Matthew Neal / Hendrik Thys Tel: +44 (0)20 3709 5700 Email: [email protected] RX Communications Group (US IR) Melody Carey Tel: (917) 322-2571 Email: [email protected]
